Odomzo (Sonidegib)

Sonidegib antagonizes the smoothened (SMO) receptor, a critical component of the Hedgehog signaling pathway. By blocking SMO, the drug prevents activation of downstream GLI transcription factors, thereby inhibiting the proliferation of cancer cells that rely on this pathway.

The prescribed dose of Odomzo is determined by the treating physician based on the patient’s clinical condition. Typically, a 200 mg oral capsule is taken once daily, but the exact regimen and duration are individualized and should follow the prescriber’s instructions.

Safety of Odomzo in pregnancy and lactation has not been established. It should be used only if the potential benefit justifies the potential risk to the fetus. Women of child‑bearing potential are advised to use effective contraception, and breastfeeding is generally not recommended during treatment.

To order Odomzo, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

The primary alternative to Odomzo is vismodegib, another Hedgehog pathway inhibitor. Both target SMO, but they differ in pharmacokinetic profiles, dosing schedules and specific safety considerations. Clinicians choose based on efficacy data, tolerability, drug‑interaction potential and patient‑specific factors.

Odomzo capsules should be stored at ambient temperature, below 25 °C, in the original packaging to protect them from moisture and light. Keep the container tightly closed and avoid exposure to excessive heat or humidity to maintain product stability.

Odomzo is taken orally as a whole capsule. Patients should swallow the capsule with water, with or without food, as directed by their healthcare provider. Consistency in administration time each day helps maintain steady drug levels.

Serious risks include elevated liver enzymes indicating hepatic injury, significant muscle toxicity reflected by raised creatine kinase, QT interval prolongation that can lead to arrhythmias, and rare severe skin reactions such as Stevens‑Johnson syndrome. Prompt medical attention is required if any of these occur.

Odomzo should be avoided in patients with known hypersensitivity to sonidegib or any capsule components, those with severe hepatic impairment, individuals with a prolonged QT interval, pregnant women, and patients taking contraindicated strong CYP3A4 inhibitors without medical supervision.